Filing Details
- Accession Number:
- 0001209191-21-025942
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-04-07 18:00:25
- Reporting Period:
- 2021-04-05
- Accepted Time:
- 2021-04-07 18:00:25
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1655759 | Arvinas Inc. | ARVN | Pharmaceutical Preparations (2834) | 472566120 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1753281 | Ian Taylor | C/O Arvinas, Inc. 5 Science Park, 395 Winchester Ave. New Haven CT 06511 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-04-05 | 25,000 | $16.00 | 103,645 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-04-05 | 4,100 | $66.01 | 99,545 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-05 | 16,450 | $66.80 | 83,095 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-04-05 | 4,450 | $67.56 | 78,645 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-04-05 | 9,211 | $0.00 | 9,211 | $16.00 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-04-05 | 15,789 | $0.00 | 15,789 | $16.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2028-09-25 | No | 4 | M | Direct | |
| 28,601 | 2028-09-25 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2021.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.30 to $66.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.31 to $67.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.31 to $68.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of June 1, 2017, with the remainder of the shares vesting in equal monthly installments following June 1, 2017 through June 1, 2020.
- This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested on June 28, 2019, with the remainder of the shares vesting in equal monthly installments following June 28, 2019 through June 28, 2022.
Billionaire Hedge Funds
